BioSpace News Archive

Jasper Therapeutics, Inc. today announced that, on January 31, 2024, three new employees were awarded grants of options to purchase an aggregate of 12,000 shares of voting common stock (the “Options”).

Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2023, which reflect strong pipeline acceleration, continued portfolio diversification, and momentum in our business.

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323.

Sales, in local currencies increased by 16% in APAC and 6% in EMEA, while sales in Americas decreased by 5%.

HUTCHMED Limited announced that, Inmagene Biopharmaceuticals has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 pursuant to the terms of the strategic partnership announced on January 11, 2021.

On January 29th, the results of the phase II study on Qilu Pharmaceutical’s novel anticancer drug iparomlimab and tuvonralimab were published online in Signal Transduction and Targeted Therapy.

The 2024 Kappa Delta Elizabeth Winston Lanier Award was presented to the Academic Network of Conservative Hip Outcomes Research group for 20 years of research to improve the quality of care for adolescent and young adult patients suffering from the three most common pre-arthritic hip conditions: femoroacetabular impingement, developmental dysplasia of the hip and residual Legg-Calve-Perthes Disease.

Eton Pharmaceuticals today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023 and provided a business update.